AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 133 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Follow-Up Questions
AC Immune SA 'in CEO'su kimdir?
Prof. Dr. Andrea Pfeifer 2003 'den beri şirketle birlikte olan AC Immune SA 'in Chief Executive Officer 'ıdır.
ACIU hissesinin fiyat performansı nasıl?
ACIU 'in mevcut fiyatı $2.96 'dir, son işlem günde 2.24% increased etti.
AC Immune SA için ana iş temaları veya sektörler nelerdir?
AC Immune SA Biotechnology endüstrisine ait ve sektör Health Care 'dir
AC Immune SA 'in piyasa değerlemesi nedir?
AC Immune SA 'in mevcut piyasa değerlemesi $297.7M 'dir
AC Immune SA al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 6 analist AC Immune SA için analist derecelendirmeleri gerçekleştirdi, bunlar 4 güçlü al, 4 al, 1 tut, 0 sat ve 4 güçlü sat içermektedir
